The MPN Channel

Explore the latest updates, including expert interviews, features, podcasts and e-learning

The MPN Channel on VJHemOnc is supported by Constellation Pharmaceuticals, Kartos Therapeutics, Inc. and Sierra Oncology. These supporters have no influence over the production of the content.

Latest Videos The MPN Sessions Podcasts e-Learning Presentations Subtypes Conferences Features Expert Editorial Board

Welcome to The Myeloproliferative Neoplasms (MPN) Channel

VJHemOnc brings you the newest developments in MPNs, including highly anticipated clinical research data, as well as cutting-edge diagnostic and treatment approaches presented at major international congresses. Also explore the latest clonal evolution discoveries, emerging therapies, and novel drug combinations, all in the form of exclusive video interviews, podcasts and roundtable discussions.

Subtypes

Essential Thrombocythemia
Myelofibrosis
Polycythemia Vera
Systemic Mastocytosis
Chronic Myelomonocytic Leukemia
Factoring in symptoms into managing MPNs
Ruben Mesa
Promising new MPN treatments
John Mascarenhas
A paradigm shift in the diagnosis and treatment of MPNs
Hans Hasselbalch
The MPN microenvironment
Angela Fleischman
View All Videos
Factoring in symptoms into managing MPNs
Ruben Mesa
Promising new MPN treatments
John Mascarenhas
Combining novel agents for treating myelofibrosis
Naveen Pemmaraju
Optimizing current JAK2 inhibitors in myelofibrosis
Srdan Verstovsek
View All Videos
Polycythemia vera: myths, mechanisms, and management
Jerry Spivak
Factoring in symptoms into managing MPNs
Ruben Mesa
Promising new MPN treatments
John Mascarenhas
A paradigm shift in the diagnosis and treatment of MPNs
Hans Hasselbalch
View All Videos
1:27
Ongoing trials and novel agents being explored in advanced and indolent systemic mastocytosis
Deepti Radia • 30 Aug 2022
1:46
Unmet needs and challenges in advanced systemic mastocytosis
Deepti Radia • 30 Aug 2022
2:03
The safety and efficacy of avapritinib in patients with advanced systemic mastocytosis
Deepti Radia • 30 Aug 2022
2:56
Insights into the treatment and management of advanced systemic mastocytosis
Deepti Radia • 30 Aug 2022
View All Videos
1:08
An insight into the mutational landscape and unique features of CMML
Eric Padron • 26 Aug 2022
1:26
The challenges of treating rare overlap syndromes and strategies to overcome these
Eric Padron • 26 Aug 2022
0:53
An insight into ongoing trials in CMML
Eric Padron • 26 Aug 2022
1:10
CMML: unmet needs and future outlooks
Eric Padron • 26 Aug 2022
View All Videos

Conferences

MPN Congress 2022
SOHO 2022
Texas MPN Workshop 2022
EHA 2022
ASCO 2022
TCT 2022
AACR 2022
BSH 2022
Polycythemia vera: myths, mechanisms, and management
Jerry Spivak • 26 Aug 2022
Factoring in symptoms into managing MPNs
Ruben Mesa • 26 Aug 2022
Promising new MPN treatments
John Mascarenhas • 26 Aug 2022
Combining novel agents for treating myelofibrosis
Naveen Pemmaraju • 26 Aug 2022
View All Videos
1:54
The potential role of cellular therapies and vaccines in the future treatment of MPNs
Srdan Verstovsek • 28 Sep 2022
1:29
The current role of allogeneic transplantation in MF
Haris Ali • 5 Oct 2022
1:15
The safety and efficacy of peritransplantation ruxolitinib in patients with MF
Haris Ali • 5 Oct 2022
3:00
The promise of momelotinib in the treatment of myelofibrosis
Prithviraj Bose • 30 Sep 2022
View All Videos
COVID-19 and MPNs: updates from the ELN study
Tiziano Barbui • 30 Sep 2022
Clinical risk factors for disease progression in MPNs
Andrew Kuykendall • 30 Sep 2022
Thrombosis and COVID-19 in MPN patients
Valerio De Stefano • 30 Sep 2022
Mitigating COVID-19 infection risk for MPN patients
Laura Michaelis • 30 Sep 2022
View All Videos
1:44
Emerging novel agents for the treatment of mastocytosis
Tracy George • 12 Jun 2022
1:56
The impact of SF3B1 mutations in myelofibrosis
Jayastu Senapati • 13 Jun 2022
2:13
The future of MPN treatment: exciting agents and targets being investigated
Srdan Verstovsek • 22 Jun 2022
1:49
Unmet needs and challenges in mastocytosis
Tracy George • 12 Jun 2022
View All Videos
3:19
Therapeutic options following failure to JAK inhibitors
Ciro Rinaldi • 6 Jun 2022
1:20
MPNs at ASCO 2022: cytopenic myelofibrosis, non-JAK inhibitor approaches & combination therapy
Ciro Rinaldi • 6 Jun 2022
2:00
Expression of CD47 and CALR in MPNs
Ciro Rinaldi • 6 Jun 2022
1:08
Key takeaways in hemonc at ASCO 2022
Naveen Pemmaraju • 5 Jun 2022
View All Videos
3:30
Unmet needs in MF: managing anemia & improving the efficacy of first and second-line treatments
Srdan Verstovsek • 25 Apr 2022
3:02
Current and emerging management strategies in polycythemia vera
Srdan Verstovsek • 25 Apr 2022
2:26
Targeting chronic inflammation in MPNs
Srdan Verstovsek • 25 Apr 2022
3:43
Momelotinib: a promising drug for patients with myelofibrosis
Srdan Verstovsek • 25 Apr 2022
View All Videos
1:49
Managing treatment toxicities when developing novel agents for MPNs
Naveen Pemmaraju • 11 Apr 2022
1:44
Upcoming trials and novel agents in MPNs
Ruben Mesa • 11 Apr 2022
1:33
The need for novel therapeutic agents in myeloproliferative neoplasms
Naveen Pemmaraju • 11 Apr 2022
1:18
Novel approaches for the treatment of myelofibrosis: navitoclax + ruxolitinib
Naveen Pemmaraju • 11 Apr 2022
View All Videos
1:31
Novel treatment agents and how they’re changing the MPN field
Claire Harrison • 4 Apr 2022
3:05
Recent updates in the MPN field: clinical trials, novel agents, and more
Claire Harrison • 4 Apr 2022
2:56
Session highlights: difficult scenarios in the myeloproliferative spectrum
Claire Harrison • 4 Apr 2022
View All Videos

The MPN Channel on VJHemOnc is supported by Constellation Pharmaceuticals, Kartos Therapeutics, Inc. and Sierra Oncology.

These supporters have no influence over the production of the content.

If you are interested in becoming a supporter of The MPN Channel, please contact us.

VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals